ストックスクリーナーアプリを入手
3.45
1.02%
0.03
アフターアワーズ：
3.40
-0.05
-1.45%
前日終値:
$3.42
開ける：
$3.41
24時間の取引高:
537.75K
Relative Volume:
0.98
時価総額：
$154.10M
収益：
-
当期純損益:
$-32.74M
株価収益率:
-4.2073
EPS:
-0.82
ネットキャッシュフロー:
$-24.89M
1週間 パフォーマンス:
-0.43%
1か月 パフォーマンス:
-34.69%
6か月 パフォーマンス:
-70.79%
1年 パフォーマンス:
-66.23%
1日の値動き範囲:
$3.35
$3.48
1週間の範囲:
$3.35
$3.56
52週間の値動き範囲:
$3.18
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
名前
Third Harmonic Bio Inc
セクター
電話
(209) 727-2457
住所
1700 MONTGOMERY STREET, SAN FRANCISCO
THRD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
3.45 | 154.10M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-11 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-08-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-07 | 開始されました | Raymond James | Outperform |
| 2022-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-15 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | 開始されました | Cowen | Outperform |
| 2022-10-10 | 開始されました | Jefferies | Buy |
| 2022-10-10 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Third Harmonic Bio Inc (THRD) 最新ニュース
Layoff Tracker: BMS’ Latest Cuts in New Jersey Will Affect 223 Employees - BioSpace
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20 - Marketscreener.com
Third Harmonic and Inventiva slash workforces - The Pharma Letter
Third Harmonic Bio progresses THB335 to Phase 2 trial By Investing.com - Investing.com Nigeria
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty - MSN
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty By Investing.com - Investing.com Canada
Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns - TipRanks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns - TipRanks
Third Harmonic Bio Inc (THRD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stock market news: Fluence Energy -47.86%, Columbus McKinnon -40.83% among biggest losers during midday trading - Business Upturn
Third Harmonic stock rating cut by Raymond James By Investing.com - Investing.com South Africa
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set -February 11, 2025 at 10:34 am EST - Marketscreener.com
Stock market today: Fluence Energy -46.44%, Columbus McKinnon -42.05% among biggest losers in early trading - Business Upturn
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Third Harmonic Bio stock tumbles after clinical trial results - Investing.com
Hain Celestial Group Inc’s Mixed Bag: Down -43.22% in 6 Months, Down -22.12% in 30 Days - The InvestChronicle
Third Harmonic Bio stock tumbles after clinical trial results By Investing.com - Investing.com South Africa
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects - Fierce Biotech
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update - The Manila Times
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate - The Bakersfield Californian
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 -February 11, 2025 at 07:00 am EST - Marketscreener.com
(THRD) Investment Analysis - Stock Traders Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
After Falling -7.79% During The Past Week, Should You Still Buy Third Harmonic Bio Inc (NASDAQ: THRD)? - Marketing Sentinel
Analytical Overview: Orasure Technologies Inc (OSUR)’s Ratios Tell a Financial Story - The Dwinnex
Balance Sheet Insights: Chart Industries Inc (GTLS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Ratios Reveal: Breaking Down Third Harmonic Bio Inc (THRD)’s Financial Health - The Dwinnex
Third Harmonic Bio Inc (THRD) 財務データ
収益
当期純利益
現金流量
EPS
Third Harmonic Bio Inc (THRD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
| BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
2.95%
0.31%
大文字化:
|
ボリューム (24 時間):